Rhythm Pharmaceuticals Inc. (RYTM)
$107.17
$-5.36
(-4.76%)
As on 28-Aug-2026 16:00EDT
Market cap
$7,574 Mln
Revenue (TTM)
$240 Mln
P/E Ratio
--
P/B Ratio
72.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-12.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.1
-
Face value
--
-
Shares outstanding
68,852,082
10 Years Aggregate
CFO
$-829.54 Mln
EBITDA
$-938.69 Mln
Net Profit
$-852.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 0.1 | 1.0 | 17.2 | 4.8 | 60.7 | 52.6 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 91.2 | 21.6 | 57.9 | 191.8 | -66.4 | 29.5 | -14.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
|
107.2 | 7,573.7 | 239.9 | -205.4 | -77.4 | -84.3 | -- | 72.8 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 246.7 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.2 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.3 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 350.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 534.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4... receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read more
-
Chairman, President & CEO
Dr. David P. Meeker M.D.
-
Chairman, President & CEO
Dr. David P. Meeker M.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Rhythm Pharmaceuticals (RYTM)
What is the current share price of Rhythm Pharmaceuticals Inc (RYTM) Today?
The share price of Rhythm Pharmaceuticals Inc (RYTM) is $107.17 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Rhythm Pharmaceuticals Inc (RYTM) has given a return of 60.69% in the last 3 years.
What is the current PB & PE ratio of Rhythm Pharmaceuticals Inc (RYTM)?
Since, TTM earnings of Rhythm Pharmaceuticals Inc (RYTM) is negative, P/E ratio is not available.
The P/B ratio of Rhythm Pharmaceuticals Inc (RYTM) is 72.79 times as on 21-Aug-2026, a 1261 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-36.42 |
26.51 |
2024 |
-13.23 |
20.96 |
2023 |
-14.74 |
16.03 |
2022 |
-9.05 |
6.20 |
2021 |
-7.38 |
1.77 |
What is the 52 Week High and Low of Rhythm Pharmaceuticals Inc (RYTM)?
The 52-week high and low of Rhythm Pharmaceuticals Inc (RYTM) are Rs 122.20 and Rs 74.51 as of 29-Aug-2026.
What is the market cap of Rhythm Pharmaceuticals Inc (RYTM)?
Rhythm Pharmaceuticals Inc (RYTM) has a market capitalisation of $ 7,574 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Rhythm Pharmaceuticals Inc (RYTM)?
Before investing in Rhythm Pharmaceuticals Inc (RYTM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.